International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management
- 15 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (1) , S117-S124
Abstract
The President of the International Association for the Study of Pain established a task force on cannabis and cannabinoid analgesia to systematically examine the evidence on (1) analgesic pharmacology of cannabinoids and preclinical evidence on their efficacy in animal models of injury-related or pathological persistent pain; (2) the clinical efficacy of cannabis, cannabinoids, and cannabis-based medicines for pain; (3) harms related to long-term use of cannabinoids; as well as (4) societal issues and policy implications related to the use of these compounds for pain management. Here, we summarize key knowledge gaps identified in the task force outputs and propose a research agenda for generating high-quality evidence on the topic. The systematic assessment of preclinical and clinical literature identified gaps in rigor of study design and reporting across the translational spectrum. We provide recommendations to improve the quality, rigor, transparency, and reproducibility of preclinical and clinical research on cannabis and cannabinoids for pain, as well as for the conduct of systematic reviews on the topic. Gaps related to comprehensive understanding of the endocannabinoid system and cannabinoid pharmacology, including pharmacokinetics and drug formulation aspects, are discussed. We outline key areas where high-quality clinical trials with cannabinoids are needed. Remaining important questions about long-term and short-term safety of cannabis and cannabinoids are emphasized. Finally, regulatory, societal, and policy challenges associated with medicinal and nonmedicinal use of cannabis are highlighted, with recommendations for improving patient safety and reducing societal harms in the context of pain management.Keywords
This publication has 55 references indexed in Scilit:
- Validation of self‐reported cannabis dose and potency: an ecological studyAddiction, 2013
- Cannabis Effects on Driving SkillsClinical Chemistry, 2013
- Adverse event reporting in randomised controlled trials of neuropathic pain: Considerations for future practicePain, 2013
- Increasing Delta-9-Tetrahydrocannabinol (?-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-AnalysisCurrent Drug Abuse Reviews, 2012
- Animal models of cannabinoid rewardBritish Journal of Pharmacology, 2010
- Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategiesInternational Review of Psychiatry, 2009
- Adverse effects of medical cannabinoids: a systematic reviewCanadian Medical Association Journal, 2008
- Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in BrainAnnals of the New York Academy of Sciences, 2006
- Reporting of Adverse Effects in Clinical Trials Should Be ImprovedJournal of Pain and Symptom Management, 1999
- Isolation, Structure, and Partial Synthesis of an Active Constituent of HashishJournal of the American Chemical Society, 1964